Hypermarcas (OTCMKTS:HYPMY) Sees Significant Growth in Short Interest

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 8,208 shares, an increase of 390.0% from the October 15th total of 1,675 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 84,726 shares, the short-interest ratio is currently 0.1 days.

Hypermarcas Stock Down 2.6%

OTCMKTS HYPMY opened at $4.00 on Wednesday. Hypermarcas has a twelve month low of $3.39 and a twelve month high of $5.77. The stock has a market cap of $2.82 billion, a PE ratio of 8.00 and a beta of 0.78. The firm has a 50-day simple moving average of $4.63 and a 200 day simple moving average of $4.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.26 and a current ratio of 1.86.

Analyst Ratings Changes

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Hypermarcas presently has a consensus rating of “Buy”.

View Our Latest Stock Analysis on HYPMY

Hypermarcas Company Profile

(Get Free Report)

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.

See Also

• Five stocks we like better than Hypermarcas
• Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
• Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
• Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
• Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching

Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.